Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of advanced, unresectable, or metastatic extrapulmonary neuroendocrine carcinoma (cancer that starts outside the lungs)
- Cancer must have progressed or worsened during or after your first round of systemic treatment
- At least one measurable tumor visible on imaging scans
- Good overall health and functional ability (able to care for yourself with minimal assistance)
- Adequate blood counts, liver, and kidney function confirmed by recent blood tests
- Age 18–75 years with life expectancy of at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and chemotherapy for people with neuroendocrine carcinoma that has spread or cannot be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of three drugs (an immunotherapy, a targeted therapy, and a chemotherapy) for advanced neuroendocrine carcinoma. It is designed for people whose cancer has progressed after at least one prior treatment, and aims to see if this combination can help control the cancer.
This trial tests a new drug (LBL-024) combined with standard chemotherapy for people with advanced EP-NEC, a rare type of neuroendocrine tumor. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
This trial tests a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) added to a standard chemotherapy regimen called FOLFIRI, to see if it works better than FOLFIRI alone for a rare and aggressive type of cancer called neuroendocrine carcinoma. It is for people whose cancer has progressed after a first-line chemotherapy, and aims to help slow the cancer's growth.
This trial is testing a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare type of cancer called LCNEC or EP-NEC that has spread. The goal is to see if this combination can help shrink or control the cancer and improve outcomes.
Hear when a new Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.